The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
The ED50 for stimulation of 3H-thymidine incorporation and cell proliferation by human umbilical vein endothelial cells for VEGFE has been determined to be in the range of 5 - 20 ng/ml. Specific activity: 2 x 105 units/mg.
% SDS-PAGE. Purity: > 90%, by SDS-PAGE and visualised by silver stain.
Endotoxin level: < 0.1 ng per ug of VEGFE.
Like VEGFA, VEGFE was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGFA, VEGFE can not bind to VEGF receptor-1 (Flt-1). Furthermore VEGFE can also not bind to VEGF receptor-3 (FLT-4). Therefore VEGFE is a potent angiogenic factor selectively binding to VEGF receptor –2/KDR.
Concentration information loading...
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Constituents: PBS, pH 7.4
This product is an active protein and may elicit a biological response in vivo, handle with caution.
The lyophilised VEGFE is soluble in water and most aqueous buffers. The lyophilised VEGFE should be reconstituted in PBS or medium containing at least 0.1% human or bovine serum albumin to a concentration not lower than 50 µg/ml.
Based on sequence similarity to VEGFA, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV) (Lyttle et al., 1994). Different isolates of Orf virus show significant amino acid sequence similarity to VEGFA and described as a viral virulence factor that appears to be derived from captured host genes. All eight cysteine residues of the central cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGFE proteins (Dehio et al., 1999; Wise et al., 1999). Alignment of all mammalian VEGF sequences indicated that VEGFE is distinct from the previously described VEGFs but most closely related to VEGFA.
has not yet been referenced specifically in any publications.